Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$5.93 - $7.6 $907 - $1,162
-153 Reduced 56.88%
116 $0
Q4 2021

Feb 08, 2022

SELL
$6.04 - $8.03 $6,468 - $8,600
-1,071 Reduced 79.93%
269 $1,000
Q3 2021

Nov 15, 2021

BUY
$8.02 - $11.0 $10,746 - $14,740
1,340 New
1,340 $7,000

About Cyclacel Pharmaceuticals, Inc.


  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $6.02M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.